|
|
|

| Jordan
U. Gutterman, M.D. Next
|
|
Chief,
Section of Cellular and Molecular Growth Regulation,
Professor of Medicine 
mail:
1515 Holcombe Blvd.
Box 0041
Houston,
TX 77030
phone:
713/792-2676
e-mail: jgutterm@notes.mdacc.tmc.edu
Education:
- B.A.
University of Virginia, Charlottesville, 1960
- M.D.
Medical College of Virginia, Richmond, 1964
|
| Professional
Experience : |
- 1996-Present
Chief, Section of Cellular and Molecular Growth Regulation,
Department of Molecular Therapeutics (University of Texas
M. D. Anderson Cancer Center)
- 1987-Present
Virginia H. Cockrell Professorship of Immunology (University
of Texas M. D. Anderson Cancer Center)
- 1987-1996
Professor of Medicine, Internist, Chairman (University of
Texas M. D. Anderson Cancer Center)
- 1984-1987
Professor of Medicine, Internist, Deputy Head (CIBT,University
of Texas M. D. Anderson Cancer Center)
- 1981-1986
Professor of Medicine, Internist, Section Head, Section of
Biological and Molecular Therapy, Department of Clinical Immunology
and Biological Therapy (CIBT, University of Texas M. D. Anderson
Cancer Center
- 1978-1981
Professor of Medicine, Internist, Department of Developmental
Therapeutics (University of Texas M. D. Anderson Cancer Center)
- 1974-1981
Associate Professor of Medicine and Associate Internist, Department
of Developmental Therapeutics (University of Texas M. D. Anderson
Cancer Center)
- 1972-1974
Assistant Professor of Medicine and Assistant Internist, Department
of Developmental Therapeutics (University of Texas M. D. Anderson
Cancer Center)
- 1971-1972
Faculty Associate, Department of Developmental Therapeutics
(University of Texas M. D. Anderson Cancer Center)
- 1971
Advanced Senior Fellow, Department of Developmental Therapeutics,
UT MD Anderson Cancer Center, Houston, Texas (University of
Texas M. D. Anderson Cancer Center)
- 1969-1971
Chief, Hematology-Oncology Service, Brooke General Hospital,
Fort Sam Houston, Texas
return
to top
|
| Research
Interests: |
|
The
major focus of the Section of Cellular and Molecular Growth
Regulation is directed at identification and characterization
of novel plant compounds that regulate the growth of tumor cells
and endothelial cells. The major emphasis during the past 24
months has been on the biochemical and biological characterization
of a triterpene glycoside with an unusual ester linkage obtained
from a desert legume plant from Australia. This compound, or
mixture of compounds, induces cytotoxicity against a wide range
of hematopoietic and solid tumor cell lines as well as freshly
isolated ovarian cancer cells. The triterpene compound induces
apoptosis in the Jurkat leukemia cell line. It is minimally
cytotoxic in vitro against nontransformed cells. In vivo, the
compound is extremely active in 2 chemopreventive models: the
initiation and promotion phases of the murine dimethylbenzanthracene
(DMBA) mouse skin carcinogenesis model as well as the rat aberrant
colonic crypt assay. The mechanism of action is being investigated
and focuses on the inhibition of the PI-3K pathway. This compound
also has potent in vitro and in vivo anti-inflammatory effects
and appears to inhibit activation of NF-kappaB.
Terpenoids
are natural constituents of plants and of invertebrate and vertebrate
animals. They play key roles in defense signaling by plants
against predators such as insects. The triterpenoids are often
pentacyclic compounds, usually containing complex side chains.
The sugars may not be required for in vitro antitumor activity,
but their presence may be important for water solubility and
in vivo activity.
Present
and future work includes complete purification and structural
characterization of the triterpene glycoside, metabolic labeling
studies, continued work on mechanism of action (including effects
on endothelial cells, angiogenesis, and cholesterol metabolism),
and genetic studies of sensitive and resistant cells by RNA
analysis on microarrays and DNA chips. Studies of the biological
effects of this terpenoid on model organisms are being pursued.
Based on the structure and known biology of other terpenoids
in human biology, the triterpenes may act as hormonal substances
and therefore may bind to a known or orphan nuclear receptor.
The premise
of our section is that plants have evolved to manufacture a
wide variety of secondary metabolites that act as deterrents
for dangerous predators. Many of the target pathways of these
plant metabolites have been preserved in evolution from yeast
to Drosophila to man and may be important constituents of the
malignant phenotype. Discovery of plant metabolites that interrupt
critical pathways in a cancer cell should yield exacting new
leads for drug discovery.
Thus, we
are continuing to study extracts of other arid land plants in
the hope of discovering novel compounds with unique mechanisms
of action against malignant cells or endothelial cells. This
project is part of a collaboration with the University of Arizona
(chemistry) and Boyce Thompson Plant Institute at Cornell University
(plant biology).
return
to top
|
| Selected
Publications: |
- Choubey D, Gutterman
JU. Inhibition of E2F-4/DP-1-stimulated transcription
by p202. Oncogene 15:291-301, 1997
- Choubey D, Li
S-J, Gutterman JU, Datta B, Lengyel P. Inhibition of
E2F-mediated transcription by p202. EMBO J 15:5668-5678, 1996
- Gutterman JU.
Clinical investigators: The driving force behind drug discovery.
Nat Biotechnol 15:598-599, 1997
- Kudelka AP, Levy
T, Verschraegen CL, Edwards CL, Piamsomboon S, Termrungruanglert
W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle
KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang
RA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470
administered to patients with advanced squamous cell cancer
of the cervix. Clin Cancer Res 3:1501-1505, 1997
- Mujoo K, Maneval
DC, Anderson SC, Gutterman JU. Adenoviral-mediated
p53 tumor suppressor gene therapy of human ovarian carcinoma.
Oncogene 12:1617-1623, 1996
return
to top
|
|